Related Experiment Video
Updated: Feb 15, 2026
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan
Chih-Ming Liang1, Chien-Hua Chiu2, Hsing-Ming Wang1
1Division of Hepatogastroenterology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Insights
Standard triple therapy effectively eradicates Helicobacter pylori in patients with chronic kidney disease (CKD), showing similar success rates and adverse events compared to non-CKD patients. Clinical factors did not significantly influence eradication outcomes.
Area of Science:
- Gastroenterology
- Nephrology
- Infectious Diseases
Background:
- Patients with chronic kidney disease (CKD) and Helicobacter pylori (H. pylori) infection face increased risks of gastroduodenal diseases.
- Eradication therapies are recommended for H. pylori in CKD patients to mitigate these risks.
Purpose of the Study:
- To evaluate the efficacy of a 7-day standard triple therapy for H. pylori eradication in patients with CKD (eGFR < 60 ml/min/1.73 m²).
- To identify clinical factors affecting the success rate of H. pylori eradication in CKD patients.
Main Methods:
- A total of 758 patients with H. pylori infection receiving 7-day standard triple therapy were analyzed.
- Patients were categorized into a CKD group (N=130) and a non-CKD group (N=628).
Main Results:
- H. pylori eradication rates were comparable between the CKD (85.4%) and non-CKD (85.7%) groups (p=0.933).
- Eradication rates across CKD stages (3, 4, and hemodialysis) showed no significant differences (p=0.982).
- Adverse events (3.1% vs 4.6%, p=0.433) and compliance (100.0% vs 99.8%, p=0.649) were similar between groups; no clinical factors influenced eradication success.
Conclusions:
- The 7-day standard triple therapy demonstrates comparable efficacy and safety for H. pylori eradication in CKD patients versus non-CKD patients.
- CKD status does not appear to be a significant factor influencing H. pylori eradication outcomes with standard triple therapy.
Aims:
Patients with chronic kidney disease (CKD) and Helicobacter pylori (H. pylori) infection have a higher incidence of gastroduodenal diseases and therefore are recommended to receive eradication therapies. This study aimed to assess the efficacy of a 7-day standard triple therapy in patients with CKD (eGFR < 60 ml/min/1.73 m2) and to investigate the clinical factors influencing the success of eradication.
Methods:
A total of 758 patients with H. pylori infection receiving a 7-day standard first-line triple therapy between January 1, 2013, and December 31, 2014, were recruited. Patients were divided into two groups: CKD group (N = 130) and non-CKD group (N = 628).
Results:
The eradication rates attained by the CKD and non-CKD groups were 85.4% and 85.7%, respectively, in the per-protocol analysis (p = 0.933). The eradication rate in CKD stage 3 was 84.5% (82/97), in stage 4 was 88.2% (15/17), and in those who received hemodialysis was 87.5% (14/16). There were no significant differences in the various stages of CKD (p = 0.982). The adverse events were similar between the two groups (3.1% versus 4.6%, p = 0.433). Compliance between the two groups was good (100.0% versus 99.8%, p = 0.649). There was no significant clinical factor influencing the H. pylori eradication rate in the non-CKD and CKD groups.
Conclusions:
This study suggests that the H. pylori eradication rate and adverse rate in patients with CKD are comparable to those of non-CKD patients.
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
01:24Chronic Kidney Disease II: Clinical Manifestations
01:28Chronic Kidney Disease III: Interprofessional Care
01:18Chronic Kidney Disease IV: Nursing Management
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...